Holen Sie sich die Stockscreener-App
2.40
0.83%
-0.02
Handel nachbörslich:
2.40
Schlusskurs vom Vortag:
$2.42
Offen:
$2.48
24-Stunden-Volumen:
1.31M
Relative Volume:
0.54
Marktkapitalisierung:
$814.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.80M
KGV:
-6.8571
EPS:
-0.35
Netto-Cashflow:
$-68.07M
1W Leistung:
-13.36%
1M Leistung:
-8.40%
6M Leistung:
-32.96%
1J Leistung:
+44.58%
1-Tages-Spanne:
$2.38
$2.54
1-Wochen-Bereich:
$2.38
$2.82
52-Wochen-Spanne:
$1.52
$4.1598
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
(415) 754-3517
Adresse
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Vergleichen Sie NUVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.40 | 814.49M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest - Yahoo Finance
HC Wainwright Decreases Earnings Estimates for Nuvation Bio - MarketBeat
HC Wainwright Cuts Earnings Estimates for Nuvation Bio - Defense World
Assenagon Asset Management S.A. Sells 309,176 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
JPMorgan Chase & Co. Increases Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Assenagon Asset Management S.A. Reduces Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio (NYSE:NUVB) Price Target Raised to $11.00 - Defense World
Nuvation Bio (NYSE:NUVB) Shares Down 3.8%Here's What Happened - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Down 5.6%Should You Sell? - MarketBeat
Jane Street Group LLC Decreases Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Holdings Decreased by Jane Street Group LLC - MarketBeat
HC Wainwright Predicts Stronger Earnings for Nuvation Bio - Defense World
FY2024 EPS Estimate for Nuvation Bio Increased by Analyst - MarketBeat
Nuvation Bio (NYSE:NUVB) Stock Price Down 8.3%Here's Why - MarketBeat
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Canada
Principal Financial Group Inc. Reduces Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
Nuvation Bio's (NUVB) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Nuvation Bio (NYSE:NUVB) Shares Gap UpHere's What Happened - MarketBeat
FDA progress and strong trial data drive positive outlook for Nuvation Bio stock - Investing.com Australia
Nuvation Bio (NYSE:NUVB) Given Buy Rating at HC Wainwright - Defense World
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Lelezard
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
Innovent wins second China nod for Nuvation-partnered cancer therapy - MSN
Nuvation Bio (NYSE:NUVB) Trading Up 10%Time to Buy? - MarketBeat
Innovent wins China nod for Nuvation Bio drug (NUVB:NYSE) - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Geode Capital Management LLC Boosts Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.7% last week but have benefitted from longer-term gains - Simply Wall St
Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
FDA Accepts for Priority Review Nuvation Bio’s NDA for Taletrectinib to Treat Advanced ROS1-positive Non-Small Cell Lung Cancer - Specialty Pharmacy Continuum
Nuvation Bio Inc. (NYSE:NUVB) Stock Position Raised by State Street Corp - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Stake Increased by State Street Corp - MarketBeat
FDA sets review date for Nuvation Bio’s cancer drug By Investing.com - Investing.com Nigeria
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio Inc.'s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - Marketscreener.com
Nuvation Bio’s (NUVB) Outperform Rating Reaffirmed at Wedbush - Defense World
Wedbush Reaffirms "Outperform" Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
FDA sets review date for Nuvation Bio's cancer drug By Investing.com - Investing.com Australia
FDA priority review for Nuvation Bio's taletrectinib - The Pharma Letter
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
FDA sets review date for Nuvation Bio's cancer drug - Investing.com
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):